enVVeno Medical Reports Second Quarter 2022 Financial Results and Provides Corporate Update

Author's Avatar
Aug 04, 2022

Ended the quarter with $47.2 million in cash and investments - expected to fund operations through the end of 2024, including release of topline SAVVE pivotal trial data